All In Biotech

BLA 761228 · Immunocore LTD

Kimmtrak

Tebentafusp-Tebn · Injection · Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Jan 25, 2022: To treat unresectable or metastatic uveal melanoma

Last checked: Nov 20, 2026Latest source record: Jun 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 25, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

19

2 Phase 3, 12 recruiting

FAERS reports

602

457 serious, 107 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

BOXED WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated [(see Dosage and Administration (2.2) , see Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated ( 2.2 , 5.1 ).

What it is approved for

From the label in effect Aug 20, 2026.

KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).

Mechanism: Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. The TCR arm binds to a gp100 peptide presented by human leukocyte antigen-A*02:01 (HLA-A*02:01) on the cell surface of uveal melanoma tumor cells. In vitro, tebentafusp-tebn bound to HLA-A*02:01-positive uveal melanoma cells and activated polyclonal T cells to release inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumor cells.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 25, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • KIMMTRAK · TEBENTAFUSP-TEBN 100MCG/0.5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tebentafusp" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cytokine release syndrome118
  • pyrexia107
  • disease progression73
  • hypotension70
  • rash69
  • malignant neoplasm progression61
  • chills59
  • product dose omission issue56
  • pruritus44
  • nausea40
  • vomiting36
  • death32

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20182
2022100
2023104
2024134
2025139
2026123

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Kimmtrak (Tebentafusp-Tebn) · HCPCS J9274

2024 spending

$87.1M

Beneficiaries

174

4,017 claims

Per beneficiary

$500,504

2024 ASP limit $211.79 per unit

View as table
YearSpending
2020$0
2021$0
2022$10,129,431
2023$63,236,203
2024$87,087,754

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Immunocore LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.